Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Bristol-Myers Squibb Company’s proposed $74 billion acquisition of Celgene Corporation would violate federal antitrust law.
According to the complaint, which was first announced in November 2019, the proposed acquisition would likely harm consumers in the U.S. market for treatments taken orally for moderate-to-severe psoriasis.
In the largest divestiture that the FTC or the U.S. Department of Justice has ever required in a merger enforcement matter, Bristol-Myers Squibb will divest to Amgen, Inc., for $13.4 billion, Celgene’s Otezla—the most popular oral treatment in the United States for moderate-to-severe psoriasis.
The Commission vote to approve the final order was 3-2. Commissioners Rohit Chopra and Rebecca Kelly Slaughter voted no.
The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about how competition benefits consumers or file an antitrust complaint. Like the FTC on Facebook, follow us on Twitter, read our blogs, and subscribe to press releases for the latest FTC news and resources.
Office of Public Affairs